Monthly
US$200
Billed every month
Sign in to subscribeCarbetocin Injection
As of 13 November 2026, for Carbetocin Injection, 6 applications are listed as under review at China's CDE; 3 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 15 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders15View records ↓
Under-review filings6View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers16View records ↓
API companies with A status12View records ↓
Chemical-drug catalogue
Loaded records: 15 holders; 4 in the quality-and-efficacy consistency-evaluation category, and 11 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20264805 | 2026/06/17 | 1ml:100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | Chu Xiong He Chuang Pharma Co., Ltd. romanized | 国药准字H20256210 | 2025/12/09 | 1ml：100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Zhejiang Hang Kang Pharma Co., Ltd. romanized | Zhejiang Hang Kang Pharma Co., Ltd. romanized | 国药准字H20255804 | 2025/10/28 | 1ml：100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Hubei Zhang Lian Du Lei Pharmaceutical Co., Ltd. romanized | Hubei Zhang Lian Du Lei Pharmaceutical Co., Ltd. romanized | 国药准字H20255583 | 2025/09/30 | 1ml: 100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Nuo He Cheng Hong Biopharmaceutical Co., Ltd. romanized | Sichuan Mei Da Kang Jia Le Pharma Co., Ltd. romanized | 国药准字H20249486 | 2024/12/01 | 1ml：100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Tong De Pharma Co., Ltd. romanized | Chengdu Tong De Pharma Co., Ltd. romanized | 国药准字H20249083 | 2024/10/16 | 1ml:100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Hainan Zhong He Pharma Co., Ltd. romanized | Hainan Zhong He Pharma Co., Ltd. romanized | 国药准字H20243798 | 2024/05/21 | 1ml：100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Sheng Nuo Biopharmaceutical Co., Ltd. romanized | Chengdu Sheng Nuo Biopharmaceutical Co., Ltd. romanized | 国药准字H20163001 | 2023/08/31 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Nanjing Xing Yin Pharma Group Co., Ltd. romanized | Nanjing Xing Yin Pharma Group Co., Ltd. romanized | 国药准字H20193159 | 2023/07/31 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Suzhou Tian Ma Pharmaceuticals Group Tian Ji Biopharmaceutical Co., Ltd. romanized | Suzhou Tian Ma Pharmaceuticals Group Tian Ji Biopharmaceutical Co., Ltd. romanized | 国药准字H20193373 | 2023/07/17 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| HAINAN HUALON PHARMACEUTICAL CO.,LTD | Chengdu Li Er Pharma Co., Ltd. romanized | 国药准字H20233887 | 2023/06/30 | 1ml:100μg | Generic approved under the new chemical-drug registration classification | CDE |
| CISEN PHARMACEUTICAL CO., LTD. | CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20233591 | 2023/05/19 | 1ml:100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Nanjing Kang Zhou Pharmaceuticals Technology Co., Ltd. romanized | Suzhou Erye Pharmaceutical Co., Ltd | 国药准字H20233447 | 2023/04/11 | 1ml:100μg | Generic approved under the new chemical-drug registration classification | CDE |
| Shenzhen Han Yu Pharma Co., Ltd. romanized | Shenzhen Han Yu Pharma Co., Ltd. romanized | 国药准字H20163024 | 2021/02/26 | 1ml:100μg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Hangzhou Ao Ya Bio Technology Co., Ltd. romanized | Hangzhou Ao Ya Bio Technology Co., Ltd. romanized | 国药准字H20203627 | 2020/12/02 | 1ml:100μg | Generic approved under the new chemical-drug registration classification | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 16 distinct approval numbers and 16 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20264805 | 1ml:100μg | Category B | XH01BBK007B002010101389 | NHSA |
| Nanjing Xing Yin Pharma Group Co., Ltd. romanized | 国药准字H20193159 | See source | Category B | XH01BBK007B002010101601 | NHSA |
| Suzhou Tian Ma Pharmaceuticals Group Tian Ji Biopharmaceutical Co., Ltd. romanized | 国药准字H20193373 | 1ml∶100μg | Category B | XH01BBK007B002010101669 | NHSA |
| HAINAN HUALON PHARMACEUTICAL CO.,LTD | 国药准字H20233887 | 1ml:100μg | Category B | XH01BBK007B002010102044 | NHSA |
| Chengdu Tong De Pharma Co., Ltd. romanized | 国药准字H20249083 | 1ml:100µg | Category B | XH01BBK007B002010102068 | NHSA |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20233591 | 1ml:100μg | Category B | XH01BBK007B002010104127 | NHSA |
| Guangdong Jin Cheng Jin Su Pharmaceutical Co., Ltd. romanized | 国药准字H20203627 | 1ml:100μg | Category B | XH01BBK007B002010104470 | NHSA |
| Zhejiang Hang Kang Pharma Co., Ltd. romanized | 国药准字H20255804 | 1ml:100μg | Category B | XH01BBK007B002010104642 | NHSA |
| Hainan Zhong He Pharma Co., Ltd. romanized | 国药准字H20243798 | 1ml:100μg | Category B | XH01BBK007B002010105842 | NHSA |
| Hui Ling Pharmaceutical (Zhongguo) Co., Ltd. romanized | 国药准字H20093500 | 1ml:100μg | Category B | XH01BBK007B002010107572 | NHSA |
| Chengdu Sheng Nuo Biopharmaceutical Co., Ltd. romanized | 国药准字H20163001 | See source | Category B | XH01BBK007B002010107821 | NHSA |
| Shenzhen Han Yu Pharma Co., Ltd. romanized | 国药准字H20163024 | 1ml:100μg | Category B | XH01BBK007B002010179260 | NHSA |
| Hubei Zhang Lian Du Lei Pharmaceutical Co., Ltd. romanized | 国药准字H20255583 | 1ml:100μg | Category B | XH01BBK007B002010181000 | NHSA |
| Nanjing Kang Zhou Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20233447 | 1ml:100μg | Category B | XH01BBK007B002010183233 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20256210 | 1ml:100μg | Category B | XH01BBK007B002010184547 | NHSA |
| Hainan Tong Yong San Yang Pharma Co., Ltd. romanized | 国药准字H20249486 | 1ml:100μg | Category B | XH01BBK007B002010184983 | NHSA |
| HAINAN HUALON PHARMACEUTICAL CO.,LTD | 国药准字H20233887 | 1ml:100μg | Category B | XH01BBK007B002010202044 | NHSA |
| Chengdu Tong De Pharma Co., Ltd. romanized | 国药准字H20249083 | 1ml:100µg | Category B | XH01BBK007B002010202068 | NHSA |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20233591 | 1ml:100μg | Category B | XH01BBK007B002010204127 | NHSA |
| Guangdong Jin Cheng Jin Su Pharmaceutical Co., Ltd. romanized | 国药准字H20203627 | 1ml:100μg | Category B | XH01BBK007B002010204470 | NHSA |
| Zhejiang Hang Kang Pharma Co., Ltd. romanized | 国药准字H20255804 | 1ml:100μg | Category B | XH01BBK007B002010204642 | NHSA |
| Hui Ling Pharmaceutical (Zhongguo) Co., Ltd. romanized | 国药准字H20093500 | 1ml:100μg | Category B | XH01BBK007B002010207572 | NHSA |
| Shenzhen Han Yu Pharma Co., Ltd. romanized | 国药准字H20163024 | 1ml:100μg | Category B | XH01BBK007B002010279260 | NHSA |
| Nanjing Kang Zhou Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20233447 | 1ml:100μg | Category B | XH01BBK007B002010283233 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20256210 | 1ml:100μg | Category B | XH01BBK007B002010284547 | NHSA |
| Hainan Tong Yong San Yang Pharma Co., Ltd. romanized | 国药准字H20249486 | 1ml:100μg | Category B | XH01BBK007B002010284983 | NHSA |
| HAINAN HUALON PHARMACEUTICAL CO.,LTD | 国药准字H20233887 | 1ml:100μg | Category B | XH01BBK007B002010302044 | NHSA |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20233591 | 1ml:100μg | Category B | XH01BBK007B002010304127 | NHSA |
| Shenzhen Han Yu Pharma Co., Ltd. romanized | 国药准字H20163024 | 1ml:100μg | Category B | XH01BBK007B002010379260 | NHSA |
| Nanjing Kang Zhou Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20233447 | 1ml:100μg | Category B | XH01BBK007B002010383233 | NHSA |
| CISEN PHARMACEUTICAL CO., LTD. | 国药准字H20233591 | 1ml:100μg | Category B | XH01BBK007B002010404127 | NHSA |
| Nanjing Xing Yin Pharma Group Co., Ltd. romanized | 国药准字H20193159 | See source | Category B | XH01BBK007B002020101601 | NHSA |
| Chengdu Sheng Nuo Biopharmaceutical Co., Ltd. romanized | 国药准字H20163001 | See source | Category B | XH01BBK007B002020107821 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 6 filings and 6 distinct first applicants.
Generic 5 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2601516 | Generic | 2026/06/26 | Not stated by source | CDE |
| Jiangxi Tai Ji Li Biopharmaceutical Co., Ltd. romanized | CYHS2602469 | Generic | 2026/10/09 | Not stated by source | CDE |
| Tianjin Tian Shi Li Zhi Jiao Pharma Co., Ltd. romanized | CYHS2601175 | Generic | 2026/05/19 | Not stated by source | CDE |
| Hui Ling Pharmaceutical (Zhongguo) Co., Ltd. romanized | CYHB2600349 | Supplement | 2026/02/13 | Not stated by source | CDE |
| Wuhan Jiu Long Pharmaceuticals Co., Ltd. romanized; Wuhan Ren Fu Pharma Co., Ltd. romanized | CYHS2503615 | Generic | 2025/10/10 | Not stated by source | CDE |
| Chengdu Tian Tai Shan Pharmaceutical Co., Ltd. romanized | CYHS2502701 | Generic | 2025/07/25 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2601516 | Generic | 2026/06/26 | Not stated by source | CDE |
| Jiangxi Tai Ji Li Biopharmaceutical Co., Ltd. romanized | CYHS2602469 | Generic | 2026/10/09 | Not stated by source | CDE |
| Tianjin Tian Shi Li Zhi Jiao Pharma Co., Ltd. romanized | CYHS2601175 | Generic | 2026/05/19 | Not stated by source | CDE |
API registrations
Non-component matches: 12 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 卡贝缩宫素 · No verified English name | Shanghai Su Hao Yi Ming Pharmaceutical Co., Ltd. romanized | Y20250000702 | I | Exact ingredient | 2025/08/08 | CDE |
| 卡贝缩宫素 · No verified English name | Hubei Zhang Lian Du Lei Pharmaceutical Co., Ltd. romanized | Y20230000581 | A | Exact ingredient | 2026/04/02 | CDE |
| 卡贝缩宫素 · No verified English name | Hainan Zhong He Pharma Co., Ltd. romanized | Y20220000880 | A | Exact ingredient | 2026/08/07 | CDE |
| 卡贝缩宫素 · No verified English name | Shandong Chen Long Pharma Co., Ltd. romanized | Y20210000924 | A | Exact ingredient | 2025/04/29 | CDE |
| 卡贝缩宫素 · No verified English name | Chengdu Tian Tai Shan Pharmaceutical Co., Ltd. romanized | Y20210000802 | A | Exact ingredient | 2026/06/25 | CDE |
| 卡贝缩宫素 · No verified English name | Han Yu Pharma (Wuhan) Co., Ltd. romanized | Y20210000447 | A | Exact ingredient | 2024/01/17 | CDE |
| 卡贝缩宫素 · No verified English name | Haerbin Ji Xiang Long Bio Technology Co., Ltd. romanized | Y20200001248 | A | Exact ingredient | 2023/08/21 | CDE |
| 卡贝缩宫素 · No verified English name | PolyPeptide Laboratories France | Y20190009322 | A | Exact ingredient | 2025/12/31 | CDE |
| 卡贝缩宫素 · No verified English name | PolyPeptide Laboratories France | Y20190009319 | A | Exact ingredient | 2025/12/31 | CDE |
| 卡贝缩宫素 · No verified English name | PolyPeptide Laboratories France | Y20190009318 | A | Exact ingredient | 2025/12/31 | CDE |
| 卡贝缩宫素 · No verified English name | PolyPeptide Laboratories France | Y20190009317 | A | Exact ingredient | 2025/12/31 | CDE |
| 卡贝缩宫素 · No verified English name | Shenzhen Han Yu Pharma Co., Ltd. romanized | Y20190006054 | A | Exact ingredient | 2023/03/24 | CDE |
| 卡贝缩宫素 · No verified English name | Chengdu Sheng Nuo Biopharmaceutical Co., Ltd. romanized | Y20190005921 | A | Exact ingredient | 2025/09/16 | CDE |
| 卡贝缩宫素 · No verified English name | Zhejiang Shang Tai Biopharmaceutical Co., Ltd. romanized | Y20180000967 | A | Exact ingredient | 2026/09/23 | CDE |
| 卡贝缩宫素 · No verified English name | Suzhou Tian Ma Pharmaceuticals Group Tian Ji Biopharmaceutical Co., Ltd. romanized | Y20170000889 | A | Exact ingredient | 2024/01/25 | CDE |
| 卡贝缩宫素 · No verified English name | Nanjing Xing Yin Pharma Group Co., Ltd. romanized | Y20170000323 | A | Exact ingredient | 2024/04/18 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
-
2026/10/09Accepted
Jiangxi Tai Ji Li Biopharmaceutical Co., Ltd. romanized
CYHS2602469
Fact date: 2026/10/09 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Carbetocin Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy